Madrid, Spain

Modesto Jesus Remuinan-Blanco

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2012

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Modesto Jesus Remuinan-Blanco

Introduction

Modesto Jesus Remuinan-Blanco is a notable inventor based in Madrid, Spain. His pioneering work primarily focuses on pharmaceutical innovations, particularly in the realm of compounds for therapeutic uses against significant health challenges such as tuberculosis.

Latest Patents

Modesto holds a patent for specific compounds, referred to by the formula (I), which includes pharmaceutically acceptable salts and N-oxides. This patent details the pharmaceutical compositions comprising these compounds and their therapeutic applications, especially targeting tuberculosis. His contribution in this area represents a valuable addition to medicinal chemistry.

Career Highlights

Modesto currently works with Glaxo Group Limited, a well-respected company in the pharmaceutical industry. His role at Glaxo highlights his commitment to advancing drug development and therapeutic solutions. With a focus on innovative chemistry, he has established himself as a significant figure in the field.

Collaborations

Throughout his career, Modesto has collaborated with talented individuals such as Carlos Alemparte-Gallardo and Christopher Barfoot. These collaborations emphasize the importance of teamwork in scientific research and development, enabling breakthroughs that beneficially impact public health.

Conclusion

Modesto Jesus Remuinan-Blanco's contributions to the pharmaceutical field, particularly in developing compounds for treating tuberculosis, showcase the critical role inventors play in medical advancements. His work continues to inspire future innovations that aim to tackle pressing health issues globally.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…